67625-35-8

Basic information

• Product Name: 5-METHYL-IMIDAZO[1,2-A]PYRIDINE-2-CARBOXYLIC ACID ETHYL ESTER
• Synonyms: ETHYL 5-METHYLIMIDAZO[1,2-A]PYRIDINE-2-CARBOXYLATE;5-METHYL-IMIDAZO[1,2-A]PYRIDINE-2-CARBOXYLIC ACID ETHYL ESTER;Ethyl 5-methyl-imidazo[1,2-a] pyridine-2-;5-METHYLIMIDAZO[1,2-A]PYRIDINE-2-CARBOXYLIC ACID ETHYL ESTER, 95+%;5-Methylimidazo[1,2-α]pyridine-2-carboxylic Acid Ethyl Ester;5-methylimidazo[1,2-a]pyridine-2-carboxylate
• CAS NO: 67625-35-8
• Molecular Formula: C₁₁H₁₂N₂O₂
• Molecular Weight: 204.23
• Product Categories: blocks;Bromides;Imidazoles;Pyridines;Building Blocks;C11;Chemical Synthesis;Heterocyclic Building Blocks;New Products for Chemical Synthesis;Heterocycle-Pyridine series
• Mol File: 67625-35-8.mol

Chemical Properties

• Melting Point: 134-135
• Appearance: /
• Density: 1.19 g/cm³
• Refractive Index: 1.584
• PKA: 3.92±0.50(Predicted)
• CAS DataBase Reference: 5-METHYL-IMIDAZO[1,2-A]PYRIDINE-2-CARBOXYLIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 5-METHYL-IMIDAZO[1,2-A]PYRIDINE-2-CARBOXYLIC ACID ETHYL ESTER(67625-35-8)
• EPA Substance Registry System: 5-METHYL-IMIDAZO[1,2-A]PYRIDINE-2-CARBOXYLIC ACID ETHYL ESTER(67625-35-8)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 67625-35-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-METHYL-IMIDAZO[1,2-A]PYRIDINE-2-CARBOXYLIC ACID ETHYL ESTER is used as a building block for the synthesis of various pharmaceutical compounds due to its potential pharmaceutical and biological properties.
Used in Research and Development:
5-METHYL-IMIDAZO[1,2-A]PYRIDINE-2-CARBOXYLIC ACID ETHYL ESTER is used as a component in the research and development of new drug candidates and potential therapeutic agents, leveraging its heterocyclic structure for medicinal chemistry applications.
Used in Industrial and Laboratory Applications:
5-METHYL-IMIDAZO[1,2-A]PYRIDINE-2-CARBOXYLIC ACID ETHYL ESTER may have other industrial and laboratory applications, with its specific uses and properties varying depending on the intended application.

InChI:InChI=1/C11H12N2O2/c1-3-15-11(14)9-7-13-8(2)5-4-6-10(13)12-9/h4-7H,3H2,1-2H3

Upstream product

• 1824-81-3 2-Amino-6-methylpyridine 
• 70-23-5 ethyl Bromopyruvate 

Downstream Products

• 1123167-64-5 3-Bromo-5-methyl-imidazo[1,2-a]pyridine-2-carboxylic acid ethyl ester 
• 118001-86-8 4-[(E)-2-(5-Methyl-imidazo[1,2-a]pyridin-2-yl)-vinyl]-benzaldehyde 
• 118000-44-5 5-methylimidazo[1,2-a]pyridine-2-carbaldehyde 
• 859788-98-0 5-bromomethyl-3-(2-ethoxy-phenyl)-2H-2,4,4b,9-tetraaza-fluoren-1-one 
• 859788-43-5 3-(2-ethoxy-benzoylamino)-5-methyl-imidazo[1,2-a]pyridine-2-carboxylic acid amide 
• 859788-72-0 3-(2-ethoxy-phenyl)-5-methyl-2H-2,4,4b,9-tetraaza-fluoren-1-one 
• 88751-06-8 5-Methyl-imidazo[1,2-a]pyridine-2-carboxylic acid 
• 872363-02-5 (5-methylimidazo[1,2-a]pyridin-2-yl)methanol 
• 118001-83-5 4-[(E)-2-(5-Methyl-imidazo[1,2-a]pyridin-2-yl)-vinyl]-benzonitrile 

Relevant articles and documents

Enantioselective Hydrogenation of Imidazo[1,2-a]pyridines

The enantioselective synthesis of tetrahydroimidazo[1,2-a]pyridines by direct hydrogenation was achieved using a ruthenium/N-heterocyclic carbene (NHC) catalyst. The reaction forgoes the need for protecting or activating groups, proceeds with complete regioselectivity, good to excellent yields, enantiomeric ratios of up to 98:2, and tolerates a broad range of functional groups. 5,6,7,8-Tetrahydroimidazo[1,2-a]pyridines, which are found in numerous bioactive molecules, were directly obtained by this method, and its applicability was demonstrated by the (formal) synthesis of several functional molecules.

Direct arylation of imidazo[1,2-a ]pyridine at C-3 with aryl iodides, bromides, and triflates via copper(I)-catalyzed C-H bond functionalization

A convenient method for the copper(I)-catalyzed arylation of substituted imidazo[1,2-a]pyridine has been developed. This method is applicable to a variety of aryl electrophiles, including bromides, iodides, and triflates. It represents the first general p

SUBSTITUTED HETEROARYL FUSED DERIVATIVES AS PI3K INHIBITORS

The present invention provides fused derivatives of Formula (I) that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PBKs including, for example, inflammatory disorders, immune- based disorders, cancer, and other diseases.

HETEROCYCLES AS POTASSIUM CHANNEL MODULATORS

Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides heterocycles, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders (e.g., migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, seizure, retinal degeneration, hearing and vision loss, Alzheimer's disease, age-related memory loss, learning deficiencies, anxiety, neuronal degeneration and motor neuron diseases, maintaining bladder control or treating urinary incontinence) and as neuroprotective agents (e.g., to prevent stroke and the like) by modulating potassium channels associated with the onset or recurrence of the indicated conditions.

Synthesis and phosphodiesterase 5 inhibitory activity of novel pyrido[1,2-e]purin-4(3H)-one derivatives

Synthesis and primary SAR of a novel series of 2-phenylpyrido[1,2-e]purin- 4(3H)-one derivatives with piperazinyl sulfonamide substituents were described herein. As potential PDE5 inhibitors for erectile dysfunction (ED) treatment, representative compound

NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS

The present invention relates to novel compounds of formula (I) wherein W, n, X and W’ are defined in the description; invention compounds are modulators of metabotropic glutamate receptors - subtype 5 (“mGluR5”) which are useful for the treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.